OCT guided vs. COmplete pci in patieNts with sT segment elevation myocArdial infarCtion and mulTivessel disease: OCT-CONTACT RCT

医学 传统PCI 心脏病学 经皮冠状动脉介入治疗 心肌梗塞 内科学 狼牙棒 罪魁祸首 部分流量储备 随机对照试验 血运重建 临床终点 冠状动脉造影
作者
Mario Iannaccone,Ovidio De Filippo,Andrea Montabone,Giorgio Marengo,Ludovica Maltese,Fabrizio Ugo,Giorgio Quadri,Maro MENNUNI,Gioel Gabrio Secco,Vittorio Taglialatela,Sebastian Cinconze,Claudio Moretti,Alessandra Truffa,Alfonso Gambino,Giacomo Boccuzzi,Vincenzo Infantino,Federico Conrotto,Alessandro Lupi,Ferdinando Varbella,Giuseppe Patti
出处
期刊:Minerva cardiology and angiology [Edizioni Minerva Medica]
卷期号:71 (4) 被引量:4
标识
DOI:10.23736/s2724-5683.22.06144-0
摘要

In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion significantly reduces the risk of cardiovascular death. However, the management of non-culprit lesions in patients with the multivessel disease remains a matter of debate in this setting. It's still unclear if a morphological OCT-guided approach, identifying coronary plaque instability, may provide a more specific treatment compared with a standard angiographic/functional approach.OCT-Contact is a prospective, multicenter, open-label, non-inferiority randomized controlled trial. Patients with STEMI with successful primary PCI of the culprit lesion will be enrolled after the index PCI. Patients will be deemed eligible if a critical coronary lesion other than the culprit (associated with a diameter of stenosis ≥50%) will be identified during the index angiography. Patients will be randomized in a 1:1 fashion to OCT-guided PCI of non-culprit lesions (Group A) vs. complete PCI (Group B). PCI in group A will be undertaken according to criteria of plaque vulnerability, while in group B the use of fractional flow reserve will be left at the operators' discretion. Major-adverse cardiovascular events (MACE) are a composite of all-cause mortality, non-fatal myocardial infarction (MI) (excluding peri-procedural MI), unplanned revascularization, and NYHA IV heart failure) will be the primary efficacy outcome. Single components of MACE along with cardiovascular mortality will be the secondary endpoints. . Safety endpoints will embrace worsening of renal failure, procedural complications, and bleedings. Patients will be followed for 24 months after randomization.A sample size of 406 patients (203 per group) is required to provide the analysis an 80% power to detect a non-inferiority in the primary endpoint with an alpha error set at 0.05 and a non-inferiority limit of 4%.A morphological OCT-guided approach may be a more specific treatment compared with the standard angiographic/functional approach in non-culprit lesions of STEMI patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
TOT完成签到,获得积分10
1秒前
太阳完成签到,获得积分10
1秒前
小川完成签到,获得积分10
2秒前
晨昏蒙影完成签到 ,获得积分10
3秒前
4秒前
syr完成签到,获得积分10
4秒前
小悦完成签到 ,获得积分10
5秒前
汪洋完成签到,获得积分10
6秒前
zss完成签到 ,获得积分10
6秒前
任全强完成签到,获得积分10
6秒前
研友_Zb1rln完成签到,获得积分10
7秒前
愉快的朝雪完成签到,获得积分10
7秒前
月军完成签到,获得积分10
8秒前
9秒前
天空之境完成签到 ,获得积分10
9秒前
zhangsansan发布了新的文献求助10
10秒前
10秒前
科研通AI6.4应助cds采纳,获得10
10秒前
帅气无敌的小丁完成签到,获得积分10
12秒前
高高的咖啡豆完成签到 ,获得积分10
12秒前
jmy完成签到,获得积分10
13秒前
xqx发布了新的文献求助10
13秒前
小太阳完成签到,获得积分10
14秒前
MAD666完成签到,获得积分10
14秒前
ZZ完成签到,获得积分20
14秒前
熊熊发布了新的文献求助10
15秒前
淡淡的问筠完成签到 ,获得积分10
15秒前
研友_VZG7GZ应助xqx采纳,获得10
17秒前
gy完成签到,获得积分10
18秒前
18秒前
草珊瑚完成签到 ,获得积分20
18秒前
sylinmm完成签到,获得积分10
19秒前
yiluyouni完成签到,获得积分10
20秒前
20秒前
Findme发布了新的文献求助60
21秒前
ZC完成签到,获得积分10
21秒前
junjun完成签到,获得积分10
23秒前
AK完成签到 ,获得积分10
23秒前
NexusExplorer应助瘦瘦的枫叶采纳,获得10
23秒前
luluyang完成签到 ,获得积分0
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Essentials of Carbohydrate Chemistry and Biochemistry, 4th Edition 800
Organizational Behavior 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
CLSI VET01S-2024 Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals (7th Ed) 500
DIPPR Project 801 - Full Version 380
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 化学工程 工程类 有机化学 物理 复合材料 生物化学 内科学 细胞生物学 基因 遗传学 免疫学 冶金 光电子学 癌症研究
热门帖子
关注 科研通微信公众号,转发送积分 7765974
求助须知:如何正确求助?哪些是违规求助? 9309963
关于积分的说明 20313419
捐赠科研通 7350773
什么是DOI,文献DOI怎么找? 3315010
关于科研通互助平台的介绍 2464543
邀请新用户注册赠送积分活动 2329592